Real-World Evidence in Type 2 Diabetes: Focus on SGLT2 inhibitors and GLP-1 Receptor Agonists

Advertisement

---

A Retrospective Real-World Study of Dapagliflozin Versus Other Oral Antidiabetic Drugs Added to Metformin in Patients with Type 2 Diabetes

Huan Huang, PhD;Kelly F. Bell, PharmD, MSPhr;Ray Gani, PhD;Cathy W. Tugwell, RN, BSN;James M. Eudicone, MS, MBA;Michelle R. Krukas-Hampel, MA

April 14th 2018

ArticleARTICLES

---

Eligibility Varies Among the 4 Sodium-Glucose Cotransporter-2 Inhibitor Cardiovascular Trials: Implications for the General Type 2 Diabetes US Population

Eric T. Wittbrodt, PharmD, MPH;James M. Eudicone, MS, MBA;Kelly F. Bell, PharmD, MSPhr;Devin M. Enhoffer, PharmD;Keith Latham, PharmD;Jennifer B. Green, MD

April 14th 2018

ArticleARTICLES

---

Generalizability of Glucagon-Like Peptide-1 Receptor Agonist Cardiovascular Outcome Trials Enrollment Criteria to the US Type 2 Diabetes Population

Eric T. Wittbrodt, PharmD, MPH;James M. Eudicone, MS, MBA;Kelly F. Bell, PharmD, MSPhr;Devin M. Enhoffer, PharmD;Keith Latham, PharmD;Jennifer B. Green, MD

April 14th 2018

ArticleARTICLES

---

Comparison of Low-Dose Liraglutide Use Versus Other GLP-1 Receptor Agonists in Patients Without Type 2 Diabetes

Eric T. Wittbrodt, PharmD, MPH;James M. Eudicone, MS, MBA;Sepehr Farahbakhshian, MS;Carrie McAdam-Marx, PhD, MSCI, RPh

April 14th 2018

ArticleARTICLES

---

Real World Evidence in Type 2 Diabetes: Focus on SGLT2 Inhibitors and GLP-1 Receptor Agonist Participating Faculty

April 14th 2018

ArticleAUTHOR INDEX